Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
19 results
D2.76 - Disease Control, Activity and Quality of Life in Chronic Spontaneous Urticaria A Cross-Sectional Study from Kazakhstan
D2.77 - Lanadelumab in C1-Esterase Inhibitor Non-Responding patient: A Case Report
D2.83 - Management of Non IgE Cow's Milk Allergy: Current Practices and Challenges
D2.75 - Prevalence of Attention Deficit Hyperactivity Disorder and Related Factors in Children Aged 6-14 Years Diagnosed with Allergic Rhinitis
D2.78 - Comparative analysis of IgE reactivity to fish extracts versus beta-parvalbumin molecules in allergic patients
D2.82 - Analytical Performance Evaluation of Cor a 8, Cor a 9, and Cor a 14 Hazelnut Components on IMMULITE 2000 XPi*
D2.84 - Avoiding Mislabeling of Drug Allergy in Patients with Recurrent Cutaneous Symptoms
D2.85 - Analytical Performance Evaluation of Bet v 4 and Cor a 1 on IMMULITE 2000 XPi*
D2.86 - Nasal Nitric Oxide in Routine Practice: Results of a One-Year Clinical Experience in Pediatric Allergology
D2.89 - Basophil Testing Beyond Positivity: Are There More Endotypes in Chronic Spontaneous Urticaria?
D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study
D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients
D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab
D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case
D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study
D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey
D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation
D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report
D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months
Download the app
The congress at your fingertips
Available on
Download